Biovectra, Inc.February 17, 2017

FDA 483 - Biovectra, Inc. - February 17, 2017

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Biovectra, Inc.

Record Details

An FDA inspection of BioVectra Inc. in Charlottetown, PE, Canada, identified a significant issue with the firm's stability program. The company consistently failed to complete stability testing in a timely manner for several batches of Bulk API. This indicates a failure to follow their own standard operating procedures for administering a stability program.

Company: Biovectra, Inc.
Inspection Date: February 17, 2017
Product Type: Drugs
Office: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
People: Tonya R. Johnson (Chemist)
Stacie A. Woods (Account Director)

Open in Dashboard

ID · 3bf401c7-eb39-461b-8c0f-cdd5e373fe9b